MYCN and cancer: CD532, an AURKA kinase-independent confirmation-specific inhibitor, disrupts the AURKA-MYCN complex and drives the proteasomal degradation of MYCN in MYCN-driven cancers [40], suggesting a strategy to overcome AURKA kinase-independent oncogenic activity by disrupting protein-protein interactions.